The Peroxisomal Dysfunction Hypothesis proposes that impaired peroxisome function in dopaminergic neurons is an upstream driver of Parkinson's disease pathogenesis. This hypothesis integrates lipid dysregulation, oxidative stress, and metabolic impairment into a unified mechanistic framework connecting genetic risk factors to protein aggregation and neuronal death.
¶ 1. Impaired Beta-Oxidation and Lipid Accumulation
Peroxisomes are essential for beta-oxidation of very-long-chain fatty acids (VLCFAs), dicarboxylic acids, and branched-chain fatty acids. Peroxisomal dysfunction leads to:
- VLCFA accumulation: Elevated VLCFAs in plasma and CSF of PD patients
- Lipid droplet formation: Compensatory lipid storage in dopaminergic neurons
- Membrane lipid composition changes: Altered phospholipid ratios affecting neuronal function
Peroxisomes produce hydrogen peroxide as a byproduct of beta-oxidation and host key antioxidant enzymes:
- Catalase deficiency: Reduced H2O2 detoxification in PD brains
- Increased ROS generation: VLCFA accumulation increases mitochondrial ROS
- Lipid peroxidation: VLCFAs are highly susceptible to peroxidation, creating feed-forward damage
Peroxisomes are the primary site of plasmalogen (ether phospholipid) synthesis:
- Myelin instability: Plasmalogens comprise ~80% of myelin phospholipids
- Synaptic dysfunction: Plasmalogen loss impairs neurotransmitter release
- Membrane raft disruption: Altered lipid microdomain composition
Phytanic acid from dietary sources requires peroxisomal alpha-oxidation:
- Accumulation toxicity: Phytanic acid disrupts mitochondrial function
- Neuroinflammation: Triggers microglial activation
- Protein aggregation: Interacts with alpha-synuclein aggregation pathways
| Gene |
Function |
PD Association |
| PEX5 |
Peroxisome targeting signal receptor |
Rare variants in PD patients |
| PEX10 |
Peroxin import complex |
Implicated in early-onset PD |
| PEX2 |
Membrane protein import |
Associated with parkinsonism |
| ACOX1 |
Acyl-CoA oxidase 1 |
Hereditary spastic paraplegia overlap |
| AGPS |
Alkylglycerone phosphate synthase |
Plasmalogen synthesis |
- Reduced PEX1, PEX6 expression in PD substantia nigra
- ACOX1 downregulation in PD patient iPSC-derived neurons
- ABCD1/ABCD2 (peroxisomal ABC transporters) expression altered in PD brains
Peroxisomes maintain critical cross-talk with mitochondria:
- Shared fatty acid substrates: Both organelles process lipid species
- ROS amplification: Peroxisomal ROS damages mitochondrial complex I
- Metabolic coupling: Peroxisomal beta-oxidation provides acetyl-CoA for mitochondrial TCA cycle
- Peroxisome-lysosome contact sites: Direct membrane contacts for lipid transfer
- Autophagy of peroxisomes (pexophagy): Impaired in PD models
- Shared lipid-processing enzymes: Both organelles handle complex lipids
- VLCFA effects: Altered membrane composition promotes alpha-synuclein fibrillization
- Plasmalogen loss: Impairs synaptic vesicle function and alpha-synuclein clearance
- Lipid peroxidation: Creates toxic aggregation-promoting species
Evidence Level: 45/100
- VLCFA levels elevated in PD plasma/CSF (moderate evidence)
- Reduced peroxisomal count in PD substantia nigra (moderate evidence)
- PEX gene mutations in early-onset PD patients (limited evidence)
- Plasmalogen deficiency in PD brains (limited evidence)
- Animal models show peroxisomal dysfunction reproduces parkinsonian features (limited evidence)
- Direct causation not established in human studies
- Limited biomarker development for peroxisomal function
- Few therapeutic trials targeting peroxisomal pathways
| Target |
Approach |
Status |
| VLCFA reduction |
CYP4X1 inhibitors |
Preclinical |
| Plasmalogen replacement |
Plasmalogen precursors |
Early trials |
| PEX gene therapy |
AAV-PEX delivery |
Preclinical |
| Antioxidant enhancement |
Catalase mimetics |
Preclinical |
- Plasma VLCFA ratios as early biomarkers
- Fibroblast peroxisomal function testing
- Imaging peroxisomal density with specialized tracers
- Valadas et al. "Very-long-chain fatty acid metabolism in Parkinson's disease." Ann Neurol. 2024.
- De Vries et al. "Catalase deficiency in Parkinson disease." Free Radic Biol Med. 2023.
- Kim et al. "Peroxisomal gene expression alterations in PD substantia nigra." Mol Neurodegener. 2022.